RevOpsis Therapeutics closed its first seed funding round and raised $16.5 million to advance RO-104, its lead candidate for the treatment of neovascular age-related macular degeneration.
The funding includes $7.5 million in non-dilutive capital, according to a press release, and will be used to complete the investigational new drug-enabling studies to secure FDA authorization and to conduct the first-in-human trials of RO-104, which are on track for 2025.
RO-104 is a trispecific biologic designed to address three angiogenic pathways, VEGF-A, VEGF-C and Ang-2, that drive retinal vascular